Available compounds per July 2021
–
| Drug | Target genes |
| Abemaciclib | CCND1, CCND3, CDK4, CDK6, CCND2, CCND1 3’UTR |
| Alectinib | ALK |
| Alpelisib | PIK3CA, PIK3R1/2, PTEN, AKT, TSC1/2 |
| Atezolizumab + bevacizumab | TMB-H / HML – ≥ 16 mut/Mb |
| Axitinib | KDR, FLT4 |
| Crizotinib | ALK, MET, MST1R, ROS1 |
| Dabrafenib | BRAF V600 |
| Dabrafenib + trametinib | BRAF V600 |
| Dacomitinib | EGFR, HER2, HER4 |
| Erlotinib | EGFR |
| Entrectinib | ROS1 |
| Lenvatinib | FGFR1, FGFR2, FGFR3, FGFR4 |
| Lorlatinib | ALK, ROS1 |
| Nilotinib | KIT, ABL1, PDGFRa, PDGFRb |
| Nivolumab | MSI-H |
| Nivolumab + ipilimumab | HML: > 199 and < 1000 TMB-H: 15 – 39 (TSO500) or 11 – 24 (Oncomine pane) |
| Olaparib | ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L |
| Panitumumab | RAF/RAS wildtype |
| Pembrolizumab | HML |
| Regorafenib | RET, KIT, FLT1, BRAF |
| Rucaparib | BRCA1, BRCA2, RAD51C, RAD51D, PALB2 |
| Sunitinib | CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET |
| Talazoparib | ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, PRA1, HRD signature |
| Trametinib | MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, NRAS, GNA11, GNAQ, GNAS, BRAF, NF1 (only gliomas) |
| Trastuzumab + pertuzumab | HER2 |
| Vemurafenib + cobimetinib | BRAF |
| Vismodegib | PTCH1 |
Overview opened cohorts
–
| Drug | Tumor type | Target | Status |
| Afatinib | NSCLC | NRG1 fusion | Closed |
| Dabrafenib | Glioblastoma | BRAF V600 mut | Open |
| Dabrafenib | Urothelial | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Cholangio | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Glioblastoma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Glioma (grade 3) | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Low grade glioma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Mamma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Neuroendocrine carcinoma colon | BRAF V600 mut | Open |
| Dabrafenib + trametinib | NSCLC | BRAF V600 mut | Closed |
| Panitumumab | (Uveal) melanoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | ACUP | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Anal cancer | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Carcinosarcoma uterus | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Cervix | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Glioblastoma | BRAF-KRAS-NRAS wildtype | Closed |
| Panitumumab | Gynaecological SCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | HNSCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Meningioma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | NSCLC | BRAF-KRAS-NRAS wildtype + EGFRmut/amp | Open |
| Panitumumab | Salivary duct | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Sarcoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Thyroid | BRAF-KRAS-NRAS wildtype | Open |
| Regorafenib | Adenoid cystic carcinoma | BRAF mut | Open |
| Regorafenib | Duodenal | FLT1 amp | Open |
| Regorafenib | Esthesioneuroblastoma | RET | Open |
| Regorafenib | Melanoma | KIT mut | Open |
| Regorafenib | NSCLC | RET | Open |
| Regorafenib | NSCLC | RAF1 mut | Open |
| Regorafenib | Thymus | KIT mut | Open |
| Trametinib | ACUP | MAP3K1 mut | Open |
| Trametinib | Cervix | MAP3K1 mut | Open |
| Trametinib | Cholangio | MAP2K4 mut | Open |
| Trametinib | Colorectal | MAP2K1 mut | Open |
| Trametinib | Colorectal | MAP2K4 mut/loss | Open |
| Trametinib | Mamma | MAP3K1 mut | Open |
| Trametinib | Mamma | MAP2K4 mut/loss | Open |
| Trametinib | Neuroendocrine carcinoma | MAP3K1 mut | Open |
| Trametinib | NSCLC | MAP2K1 mut | Open |
| Trametinib | NSCLC | NRAS mut | Open |
| Trametinib | Ovarian | NRAS mut | Open |
| Trametinib | Ovarian | MAP2K4 mut | Open |
| Trametinib | Thyroid | NRAS mut | Open |
| Trametinib | Prostate | MAP3K1 mut | Open |
| Trametinib | Pleiomorphic malignancy | NRAS mut | Open |
| Trametinib | Melanocytic tumor | GNA11 mut | Open |
| Trametinib | Prostate | NRAS mut | Open |
| Trametinib | Astrocytoma | BRAF fusion | Open |
| Trametinib | Glioneural tumor | BRAF fusion | Open |
| Trametinib | Cholangio | NRAS mut | Open |
| Trametinib | NSCLC | BRAF fusion | Open |
| Trametinib | Pancreas | BRAF fusion | Open |
| Trametinib | Pancreas | MAP2K1 mut | Open |
| Trametinib | Stomach | MAP2K1 mut | Open |
| Trametinib | Pancreas | MAP2K4 loss | Open |
| Trametinib | Low grade glioma | NF1 mut | Open |
| Trametinib | Yolk sac tumor | NRAS mut | Open |
| Trastuzumab + pertuzumab | Adenoid cystic carcinoma | HER2 mut | Open |
| Trastuzumab + pertuzumab | Biliary tract | HER2 amp/mut | Open |
| Trastuzumab + pertuzumab | Cervix | HER2 mut | Open |
| Trastuzumab + pertuzumab | Cervix | HER2 amp | Open |
| Trastuzumab + pertuzumab | Colorectal | HER2 amp | Open |
| Trastuzumab + pertuzumab | Colorectal | HER2 mut | Open |
| Trastuzumab + pertuzumab | Duodenal | HER2 amp | Open |
| Trastuzumab + pertuzumab | Hidradenocarcinoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | Neuroendocrine carcinoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | NSCLC | HER2 amp | Open |
| Trastuzumab + pertuzumab | NSCLC | HER2 mut (exon 20) | Closed |
| Trastuzumab + pertuzumab | Ovarian | HER2 mut | Open |
| Trastuzumab + pertuzumab | Ovarian | HER2 amp | Open |
| Trastuzumab + pertuzumab | Salivary duct | HER2 amp | Open |
| Trastuzumab + pertuzumab | Urinary tract | HER2 amp | Open |
| Trastuzumab + pertuzumab | Urinary tract | HER2 mut | Open |
| Trastuzumab + pertuzumab | Vulva | HER2 amp | Open |
| Vemurafenib + cobimetinib | ACUP | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Erdheim Chester Disease | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | NSCLC | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | NSCLC | BRAF non-V600 mut | Open |
| Vemurafenib + cobimetinib | Ovarian | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Papillary craniopharyngioma | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Salivary duct | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Thyroid | BRAF V600 mut | Open |
| Ribociclib | Urothelial | CDKN2A loss/mut | Closed |
| Ribociclib | Ceruminous adenocarcinoma | CDKN2A loss/mut | Closed |
| Ribociclib | Ependymoma | CDKN2A loss/mut | Closed |
| Ribociclib | Melanoma | CDK4 amp | Closed |
| Ribociclib | ACUP | CDKN2A loss/mut | Closed |
| Ribociclib | Prostate | CDKN2A loss/mut | Closed |
| Ribociclib | Thymus | CDKN2A loss/mut | Closed |
| Ribociclib | Sarcoma | CDKN2A loss/mut | Closed |
| Ribociclib | Anaplastic meningioma | CDKN2A loss/mut | Closed |
| Ribociclib | Salivary glands | CDK6 amp | Closed |
| Ribociclib | Mesothelioma | CDKN2A loss/mut | Closed |
| Ribociclib | Salivary glands | CDKN2A loss/mut | Closed |
| Alpelisib | Miscellaneous tumor types | PIK3CA mut | Open |
| Alpelisib | Upper GI-tumors | PIK3CA mut | Open |
| Vismodegib | Sarcoma | PTCH1 mut | Open |
| Vismodegib | Medulloblastoma | PTCH1 mut | Open |
| Erlotinib | Glioblastoma | EGFR mut | Open |
| Erlotinib | Glioblastoma | EGFR fusion | Open |
| Erlotinib | Colorectal | EGFR mut | Open |
| Alectinib | All tumor types | ALK fusion | Open |
| Nilotinib | GIST | KIT mut | Open |
| Nilotinib | GIST | PDGFRa mut | Open |
| Nilotinib | Mesothelioma | PDGFRa mut | Open |
| Nilotinib | Colorectal | PDGFRb mut | Open |
| Nilotinib | Melanoma | KIT mut | Open |
| Lenvatinib | Colorectal | FGFR1 mut | Open |
| Lenvatinib | Cholangio | FGFR2 fusion | Open |
| Lenvatinib | Cholangio | FGFR3 fusion | Open |
| Lenvatinib | Biliary tract | FGFR2 mut | Open |
| Lenvatinib | Glioblastoma | FGFR2 fusion | Open |
| Lenvatinib | Colorectal | FGFR2 amp | Open |
| Lenvatinib | Mamma | FGFR2 amp/mut | Open |
| Lenvatinib | Mamma | FGFR1 amp | Open |
| Lenvatinib | Osteosarcoma | FGFR1 amp | Open |
| Lenvatinib | NSCLC | FGFR1 amp | Open |
| Lenvatinib | NSCLC | FGFR2 amp | Open |
| Lenvatinib | Anal cancer | FGFR3 mut | Open |
| Lenvatinib | Endometrial | FGFR2 mut | Open |
| Lenvatinib | Esophageal | FGFR2 amp | Open |
| Lenvatinib | Salivary glands | FGFR3 amp | Open |
| Lenvatinib | Neuroendocrine tumor (nasal cavity) | FGFR3 amp | Open |
| Lenvatinib | ACUP | FGFR2 fusion | Open |
| Lenvatinib | Urachus carcinoma | FGFR2 amp | Open |
| Lenvatinib | HNSCC | FGFR3 mut | Open |
| Lenvatinib | Urothelial | FGFR3 mut | Open |
| Lenvatinib | Adenoid cystic carcinoma | FGFR2 mut | Open |
| Lenvatinib | Salivary duct | FGFR2 mut | Open |
| Lenvatinib | Glioneural tumor | FGFR1 mut | Open |
| Lenvatinib | Pancreas | FGFR2 fusion | Open |
| Lenvatinib | Digital papillary carcinoma | FGFR2 mut | Open |
| Sunitinib | Thymus | KIT mut | Open |
| Sunitinib | Prostate | PDGFRa mut | Open |
| Sunitinib | Osteosarcoma | PDGFRb mut | Open |
| Sunitinib | Urothelial | FGFR1 amp | Open |
| Sunitinib | Mamma | PDGFRb amp | Open |
| Sunitinib | Adenoid cystic carcinoma | PDGFRa amp | Open |
| Sunitinib | Thyroid | PDGFRa amp | Open |
| Sunitinib | Ovarian | FGFR1 amp | Open |
| Sunitinib | Colorectal | CSF1R mut | Open |
| Sunitinib | Colorectal | FLT3 amp | Open |
| Sunitinib | NSCLC | KIT amp | Open |
| Sunitinib | Ovarian | FGFR2 amp | Open |
| Crizotinib | Inflammatory Myofibroblastic tumor | ALK fusion | Open |
| Crizotinib | Colorectal | MET amp | Open |
| Crizotinib | Colorectal | ALK mut | Open |
| Crizotinib | Esophageal | MET amp | Open |
| Crizotinib | NSCLC | MET mut | On hold |
| Crizotinib | NSCLC | MET amp | Open |
| Crizotinib | Thyroid | ALK | Open |
| Crizotinib | Sarcoma | ALK | Open |
| Crizotinib | CUP | ALK fusion | Open |
| Crizotinib | Thyroid | MET fusion | Open |
| Crizotinib | HCC | MET amp | Open |
| Crizotinib | Gastro-esophageal junction | MET amp | Open |
| Cabozantinib | Melanoma | MET amp | Closed |
| Cabozantinib | Teratoma | MET amp | Closed |
| Cabozantinib | NSCLC | RET fusion/mut | Closed |
| Cabozantinib | GIST | NTRK2 mut | Closed |
| Cabozantinib | Esophageal | MET mut | Closed |
| Palbociclib | Colorectal | CDKN2A loss/mut | Closed |
| Palbociclib | Glioblastoma | CDKN2A loss/mut | Closed |
| Palbociclib | Cholangio | CDKN2A loss/mut | Closed |
| Palbociclib | Melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Uveal melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | PEComa | CDKN2A loss/mut | Closed |
| Palbociclib | Small intestine | CDKN2A loss/mut | Closed |
| Palbociclib | NSCLC | CCND1 amp | Closed |
| Palbociclib | Ovarian | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | SMARCA4 mut | Closed |
| Palbociclib | Vulva | CDKN2A loss/mut | Closed |
| Palbociclib | Prostate | CDK6 amp | Closed |
| Palbociclib | Melanoma | CCND1 amp | Closed |
| Palbociclib | Colorectal | SMARCA4 mut | Closed |
| Palbociclib | Renal clear cell | CDKN2A loss/mut | Closed |
| Palbociclib | Esophageal | CDK4 amp | Closed |
| Palbociclib | HNSCC | CDKN2A loss/mut | Closed |
| Palbociclib | Primitive Neuro-ectodermal tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Carcinoid/Neuroendocrine tumor | CCND1 amp | Closed |
| Palbociclib | Pancreas | CDKN2A loss/mut | Closed |
| Palbociclib | Esophageal | CDKN2A loss/mut | Closed |
| Palbociclib | NSCLC | CDKN2A loss/mut | Closed |
| Palbociclib | Sarcoma | CDK4 amp | Closed |
| Palbociclib | Astrocytoma | CDK4 amp | Closed |
| Palbociclib | Colorectal | CCND2 amp | Closed |
| Palbociclib | Prostate | CDK4 amp | Closed |
| Axitinib | Colorectal | FLT1 amp | Open |
| Abemaciclib | Urothelial | CCND1 amp | Open |
| Abemaciclib | NSCLC | CCND1 amp | Open |
| Abemaciclib | Prostate | CCND1 amp | Open |
| Abemaciclib | Melanoma | CCND1 amp | Open |
| Abemaciclib | Small intestine | CCND3 amp | Open |
| Durvalumab | All tumor types | MSI-H | Closed |
| Olaparib | All tumor types | BRCA1/2 mut/loss | Closed |
| Olaparib | All tumor types | ATM mut/loss | Open |
| Olaparib | Mamma, ovarian, prostate, pancreas, SCLC, stomach | HRR alteraions | Open |
| Olaparib | All other tumor types | HRR alteraions | Open |
| Rucaparib | Mamma | BRCA1/2, RAD51C, RAD51D and PALB2 | Open |
| Rucaparib | Ovarian | BRCA1/2, RAD51C, RAD51D and PALB2 | Open |
| Rucaparib | Prostate | BRCA1/2, RAD51C, RAD51D and PALB2 | Open |
| Rucaparib | Pancreas | BRCA1/2, RAD51C, RAD51D and PALB2 | Open |
| Rucaparib | All other tumor types | BRCA1/2, RAD51C, RAD51D and PALB2 | Open |
| Talazoparib | All tumor types | HRD signature | Open |
| Nivolumab + ipilimumab | All tumor types | HML (200 – 1000)/ H-TMB | Open |
| Nivolumab | All tumor types | MSI-H | Open |
| Nivolumab | All tumor types | HML (> 450) | Closed |
| Pembrolizumab | Colorectal | HML (140 – 290) | Closed |
| Pembrolizumab | Esophageal / Cardia / Stomach | HML (140 – 290) | Closed |
| Pembrolizumab | HNSCC | HML (140 – 290) | Open |
| Pembrolizumab | Prostate | HML (140 – 290) | Open |
| Pembrolizumab | Mamma | HML (140 – 290) | Open |
| Pembrolizumab | Miscellaneous tumor types | HML (140 – 290) | On hold |
| Pembrolizumab | All tumor types | HML > 290 | On hold |